Phase IB/II of CPX-351 for Relapse Prevention in AML
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will
continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient
remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days
pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion
of the study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborators:
Jazz Pharmaceuticals National Heart, Lung, and Blood Institute (NHLBI)